Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics

The treatment landscape of prostate cancer has changed dramatically following the advent of novel systemic therapies, most of which target the androgen receptor (AR). Agents such as abiraterone, enzalutamide, apalutamide, darolutamide were designed to further suppress androgen receptor signaling fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanayama, Mayuko, Luo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657721/
https://www.ncbi.nlm.nih.gov/pubmed/34884545
http://dx.doi.org/10.3390/ijms222312742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657721/
https://www.ncbi.nlm.nih.gov/pubmed/34884545
http://dx.doi.org/10.3390/ijms222312742

Ejemplares similares